Hostname: page-component-cd9895bd7-8ctnn Total loading time: 0 Render date: 2024-12-28T12:04:38.007Z Has data issue: false hasContentIssue false
  • English
  • Français

Ten-Year Persistence of Antibody to Hepatitis B Surface Antigen in Healthcare Workers Vaccinated Against Hepatitis B Virus, and Response to Booster Vaccination

Published online by Cambridge University Press:  02 January 2015

Ricardo Durlach ,
Stella Laugas ,
Cristina B. Freuler ,
Viviana E. Rodríguez  and
Marta Costa
Ricardo Durlach*
Affiliation:
German Hospital, Buenos Aires, Argentina
Stella Laugas
Affiliation:
German Hospital, Buenos Aires, Argentina
Cristina B. Freuler
Affiliation:
German Hospital, Buenos Aires, Argentina
Viviana E. Rodríguez
Affiliation:
German Hospital, Buenos Aires, Argentina
Marta Costa
Affiliation:
German Hospital, Buenos Aires, Argentina
*
Avenida Pueyrredon 1640, (1118) Ciudad de Buenos Aires, Argentina
Get access Rights & Permissions [Opens in a new window]

Abstract

This study estimated the number of HCWs with protective antibody levels 5 and 10 years after HBV vaccination. Kaplan-Meier probabilities of protective levels were 0.95 at 60 days after vaccination, 0.87 at 5 years, and 0.79 at 10 years. Those without protective levels displayed good response 7 and 30 days after a booster

Type
Concise Communications
Information
Infection Control & Hospital Epidemiology , Volume 24 , Issue 10 , October 2003 , pp. 773 - 776
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2003

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Center for Disease Control. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR 1991;40(RR-13):1–19.Google Scholar
2.Hadler, SC, Margolis, HS. Viral hepatitis. In: Evans, AS, ed. Viral Infections of Humans, 3rd ed. New York: Plenum; 1991:351–391.CrossRefGoogle Scholar
3.Wu, JS, Hwang, LY, Goodman, KS, Beasley, RP. Hepatitis B vaccination in high-risk infants: 10 years follow-up. J Infect Dis 1999;179:1319–1325.CrossRefGoogle Scholar
4.European Consensus Group on Hepatitis B Immunity. Are booster immunizations needed for lifelong hepatitis B immunity? Lancet 2000;355:561–565.CrossRefGoogle Scholar
5.Jilg, W, Schmidt, M, Deinhart, F. Four-year experience with a recombinant hepatitis B vaccine. Infection 1989;17:70–76.CrossRefGoogle ScholarPubMed
6.Barash, C, Conn, MI, Di Marino, AJ, Marzano, J, Allen, M. Serologic hepatitis B immunity in vaccinated health care workers. Arch Intern Med 1999;159:1481–1483.CrossRefGoogle ScholarPubMed
7.Van Herck, K, Van Damme, P, Thoelen, S, Meheus, A. Long-term persistence of anti-HBs after vaccination with a recombinant DNA yeast-derived hepatitis B vaccine: 8 years results. Vaccine 1998;16:1933–1935.CrossRefGoogle Scholar
8.Jilg, W, Schmidt, M, Dienhardt, F. Persistence of specific antibodies after hepatitis B vaccination. J Hepatol 1988;6:201–207.CrossRefGoogle ScholarPubMed
9.AIDS/TB Committee of the Society for Healthcare Epidemiology of America. Management of healthcare workers infected with hepatitis B virus, hepatitis C virus, human immunodeficiency virus or other bloodborne pathogens. Infect Control Hosp Epidemiol 1997;18:349–363.CrossRefGoogle Scholar
10.Catterall, AP, Murray-Lyon, MI. Strategies for hepatitis B immunization. Gut 1992;33:576–579.CrossRefGoogle Scholar
11.Koziol, DE, Henderson, DK. Nosocomial viral hepatitis in health care workers. In: Mayhall, CG, ed. Hospital Epidemiology and Infection Control, 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 1999:1057–1073.Google Scholar
12.Ni, YH, Chang, MH, Huang, LM, et al.Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after mass hepatitis B vaccination. Ann Intern Med 2001;135:796–800.CrossRefGoogle Scholar
13.McMahon, BJ, Hoick, P, Bulkow, L, Snowball, M. Serologic and clinical outcomes of 1536 Alaska natives chronically infected with hepatitis B virus. Ann Intern Med 2001;135:759–768.CrossRefGoogle ScholarPubMed
14.Da Villa, G, Peluso, F, Picciotto, L, Bencivenga, M, Elia, S, Pelliccia, MG. Persistence of anti-HBs in children vaccinated against viral hepatitis B in the first year of life: follow-up at 5 and 10 years. Vaccine 1996;14:1503–1505.CrossRefGoogle ScholarPubMed
15.Laugas, S, Freuler, CB, Rodriguez, VE, Durlach RA Antibody level of hepatitis B after 10 years vaccination. Presented at the 4th Decennial International Conference on Nosocomial and Healthcare Associated Infections; March 5-9, 2000; Atlanta, GAGoogle Scholar
16.Wismans, PJ, van Hartum, J, Mudde, GC, Endeman, HJ, Poel, J, de Gast, GC. Is booster injection with hepatitis B vaccine necessary in healthy responders? A study of the immune response. J Hepatol 1989;8:236–240.CrossRefGoogle ScholarPubMed
17.Wainwright, RB, Bulkow, LR, Parkinson, AJ, Zanis, C, McMahon, BJ. Protection provided by hepatitis B vaccine in a Yupik Eskimo population: results of a 10-year study. J Infect Dis 1997;175:674–677.CrossRefGoogle Scholar